2023 World Conference on Lung Cancer (Posters)-EP07.04. Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma

EP07.04. Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma - PDF(Abstract)

Back to course

Pdf Summary

This study investigates the immunomodulatory effects of OM-85 BV, a bacterial lysis product, on early-stage lung adenocarcinoma. The researchers established genetically engineered mouse models that mimic human lung nodules and early-stage lung adenocarcinoma. The mice were divided into three groups: a benign nodule control group, an early-stage lung adenocarcinoma control group, and an OM-85 BV intervention group. Tumor growth, histopathology, and immune cell distribution were analyzed using various techniques. <br /><br />The results showed that tumor growth and immune cell levels in the OM-85 BV intervention group were similar to those in the benign nodule control group, but the activation of immune cells was higher compared to the early-stage lung adenocarcinoma control group. This suggests that OM-85 BV may inhibit the progression of early lung adenocarcinoma by regulating the number and activity of T cells, natural killer cells, and macrophages.<br /><br />These findings provide evidence that OM-85 BV could be a cost-effective alternative for the treatment of early-stage lung adenocarcinoma through simple oral administration. The study highlights the importance of understanding the immune microenvironment in early-stage lung adenocarcinoma and suggests that OM-85 BV has potential as an immunomodulatory therapy for this condition.

Asset Subtitle

Dawei Yang

Meta Tag

Speaker Dawei Yang

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

immunomodulatory effects

OM-85 BV

lung adenocarcinoma

mouse models

tumor growth

immune cell distribution

T cells

natural killer cells

macrophages

oral administration